Core Insights - The article highlights the increasing investment and commitment of foreign companies in Jiangsu, China, particularly following the China International Import Expo (CIIE) [1][2][3][4][5][6][8] - It emphasizes the transformation of foreign enterprises from merely producing goods to establishing deep-rooted partnerships and ecosystems in Jiangsu, showcasing a shift in investment strategy [8] Group 1: Investment Growth - DuPont has significantly expanded its operations in Zhangjiagang, establishing an integrated production base for automotive adhesives, which began with an investment agreement at the first CIIE in 2018 [2] - Kärcher has invested 100 million yuan in Suzhou to create a global R&D center, focusing on innovations in battery and robotics, which commenced operations in 2023 [3] - AstraZeneca announced the expansion of its Qingdao base, complementing its existing facilities in Wuxi and Taizhou, solidifying its presence in China [3] Group 2: Innovation and Manufacturing - Zeiss has transitioned its Suzhou factory to produce high-end microscopes, becoming a crucial manufacturing hub for global distribution, reflecting a shift from basic to advanced manufacturing capabilities [4][5] - Schneider Electric's Wuxi factory achieved net-zero emissions ahead of schedule, highlighting the effectiveness of local manufacturing and innovation [5] - Cargill's capability development center in Nanjing has evolved over ten years into a key operational hub for its North Asia business [5] Group 3: Local Partnerships and Ecosystems - Siemens has intensified its collaboration with Jiangsu, focusing on open scenarios, talent development, and ecosystem co-creation, indicating a deeper commitment to local integration [6] - GE Aviation has invested an additional $8.5 million in its Suzhou facility to enhance production capabilities for civil aviation engine components, demonstrating a long-term strategy in the Chinese market [7] - Schott has established a new production line in Suzhou for automotive safety components, aiming to strengthen local supply chains and foster innovation [7] Group 4: Strategic Evolution - Foreign companies are evolving from a model of global business coordination to one of local ecosystem integration, with the CIIE acting as a catalyst for these strategic shifts [8]

Core Insights - The China International Import Expo (CIIE) has successfully held seven sessions, with ongoing benefits for participating companies, particularly state-owned enterprises (SOEs) [1][2] - China Resources Group has actively participated in the CIIE, achieving significant procurement agreements and expressing clear cooperation needs across various sectors [1][4] Group 1: CIIE Participation and Impact - The CIIE has become a key platform for SOEs, with their transaction intentions accounting for nearly one-fourth of the total during the past seven sessions [2] - China Resources Group has established procurement partnerships with exhibitors from 35 countries, totaling a contract value of $15.15 billion [1][2] Group 2: Business Development and Innovation - China Resources Group is focusing on full-chain cooperation needs, including R&D, supply chain, and distribution [4] - The company plans to enhance its international presence through cross-border e-commerce and strategic partnerships with global pharmaceutical firms [5] Group 3: Global Exhibitors' Confidence in China - Global exhibitors, such as Hungary's Tutti Pharma, have expressed strong confidence in the Chinese health market, with significant sales growth and product localization efforts [6][7] - New Zealand's Pacific Alpaca Group has increased its exhibition space at the CIIE, reflecting its commitment to the Chinese market [7] Group 4: Future Developments and Trends - The upcoming eighth CIIE is set to showcase innovations in medical devices and biopharmaceuticals, attracting major global pharmaceutical companies [8] - The event will focus on health products and services for the aging population, aligning with China's "Healthy China 2030" strategy [8]